Skip to Main Content

Paper Details

Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329].
Ann Oncol
0
2023
HER2CLIMB, HER2D, Tucatinib, brain metastases, capecitabine, metastatic breast cancer, patients, trastuzumab
Author NameAffiliation
Giuseppe CuriglianoIstituto Europeo di Oncologia, IRCCS University of Milano
Lisa A CareyUNC Lineberger Comprehensive Cancer Center
Gabriel N HortobagyiMD Anderson Cancer Center
Ian E KropDana-Farber Cancer Institute
Dennis J SlamonUniversity of California, Los Angeles/Jonsson Comprehensive Cancer Center
Eric P WinerDana-Farber Cancer Institute
  • 1 - 6

Datasets

Release 1.2